Harnessing the Potential of mRNA Vaccines Against Hepatitis C Virus 2309530
The Journal of Immunology · 01.08.2026 · 215 (Supplement_1)
DOI: 10.1093/jimmun/vkag141.1562 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.07.2026. Verfasst von Branka Grubor-Bauk und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Chronic hepatitis C virus (HCV) infection affects 58 million people globally and remains a major cause of cirrhosis and hepatocellular carcinoma. Aproximately 1 million new infections 250,000-related deaths occur annually, yet no vaccine exists. WHO has identified HCV as a top-priority virus requiring a vaccine to achieve viral hepatitis elimination. Increasing evidence implicates liver-resident memory CD8+ T (TRM) cells as key mediators of protection against hepatotropic pathogens. We therefore investigated whether mRNA vaccines can be engineered to establish robust intrahepatic TRM responses against HCV.
Methods
Nucleoside-modified mRNA encoding HCV genotype 3a NS5B polymerase was formulated in ALC-0315 or MC3 lipid nanoparticles (LNPs) or in DOTAP/DOPE liposomes to form lipid-complexed RNA (LPX). To enhance immunogenicity, LPX was co-formulated with the invariant NKT agonist α-galactosyl-ceramide analogue (α-GCB). BALB/c mice (n = 5/group) received 5 µg mRNA per dose: via intramuscular, intradermal or intravenous routes. HCV-specific CD8+ T cells were quantified using flow cytometry, IFN-γ ELISPOT and intracellular cytokine staining in liver and the spleen.
Results
All formulations induced systemic and intrahepatic NS5B-specific CD8+ T cells, but only LPX-mRNA induced bona fide liver TRM cells. Co-delivery with α-GCB significantly increased TRM magnitude and numbers while homologous boosting further expanded durable intrahepatic TRM cells persisting to day 60 post-vaccination.
Conclusion
This study provides the first evidence that a HCV vaccine can elicit liver-resident memory CD8+ T cells. LPX’s hepatic tropism, combined with α-GCB driven NKT activation, efficiently imprints robust, durable liver TRM responses, supporting LPX-mRNA/α-GCB as a promising, platform for next-generation HCV vaccines Funding Source ACH4 (Australia) Topic Categories Vaccines and Immunotherapy (VAC)
Zitieren
APA
Grubor-Bauk, B., Johansson, H., Masavuli, M., Minnell, J., Holz, L., Painter, G., & Hermans, I. (2026). Harnessing the Potential of mRNA Vaccines Against Hepatitis C Virus 2309530. The Journal of Immunology, 215(Supplement_1). https://doi.org/10.1093/jimmun/vkag141.1562
Vancouver
Grubor-Bauk B, Johansson H, Masavuli M, Minnell J, Holz L, Painter G, et al. Harnessing the Potential of mRNA Vaccines Against Hepatitis C Virus 2309530. The Journal of Immunology. 2026;215(Supplement_1). doi:10.1093/jimmun/vkag141.1562
BibTeX
@article{GruborBauk2026,
author = {Grubor-Bauk, Branka and Johansson, Henrik and Masavuli, Makutiro and Minnell, Jordan and Holz, Lauren and Painter, Gavin and Hermans, Ian},
title = {Harnessing the Potential of mRNA Vaccines Against Hepatitis C Virus 2309530},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {Supplement_1},
doi = {10.1093/jimmun/vkag141.1562}
}
EUVIMED